Effective April 3, 2023.
Effective on July 15, 2022.
Legislative and health policy expert brings extensive private and public sector experience.
“We are very pleased with our outstanding performance in the third quarter, driven by strong surgeon adoption and utilization of OMNI.”
The company's valuation will be more than $1B.
It's working on technology for glaucoma and dry eye disease.
The company focuses on glaucoma and dry eye disease.
And heavy on the cat eyes.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Tons of business ideas for eyecare professionals!